Atomo Diagnostics raises just $44.5K in share purchase plan amid major shortfall
What's the deal? Atomo DiagnosticsDealroom has a profile for this one. Try Dealroom → (ASX: AT1), an Australian medical device company that makes rapid diagnostic test devices, completed its share purchase plan on May 8, raising just $44,500 before costs. The company received valid applications for 1,348,480 shares at an issue price of $0.033 per share.
Participating shareholders will also receive 674,229 free attaching options, exercisable at $0.045 with a 2.5-year expiry. Eligible shareholders in Australia and New Zealand could subscribe for up to $30,000 worth of new shares.
Atomo's patented devices simplify testing procedures and improve reliability across rapid point-of-care and at-home testing applications.
Why now? The SPP was launched under a prospectus dated April 16, 2026, with a record date of March 27. CEO John Kelly said the completed raise puts the company "in a strong position to move forward with its operational activities."
What could go wrong? The numbers tell a stark story. Atomo reported a significant SPP shortfall of $955,500 — meaning it raised less than 5% of the plan's potential. The company has reserved the right to place the shortfall shares at its discretion, but the tepid response suggests limited investor appetite at current levels.
With shares priced at just 3.3 cents, Atomo is operating in micro-cap territory where liquidity and market confidence can evaporate quickly.
The signal: Atomo's sub-$50,000 raise — less than 5% of the plan's potential — is a blunt indicator of how far post-pandemic sentiment has shifted against rapid diagnostics companies. Classified as "early growth" on Dealroom despite listing on the ASX, the company's struggle to attract even modest capital at 3.3 cents a share underscores the liquidity crisis facing micro-cap medtech firms that rode the COVID testing wave but have yet to demonstrate a durable commercial path beyond it.
Read more: finnewsnetwork.com.au
